Search results

ANSTO hosted an international meeting of Expert and Policy group members for Generation IV Forum (GIF).

Imaging protocol assesses molecular mechanism of work in the treatment of deadly childhood cancer neuroblastoma.

The new Micro Computed Tomography (MCT) beamline is the first instrument to become operational as part of the $94 million Project BRIGHT program, which will see the completion of eight new beamlines at ANSTO’s Australian Synchrotron.

This scholarship recognises outstanding ability and promise in the field of nuclear science and technology, specifically as it applies to nuclear energy. Successful applicants will demonstrate a history of interest in nuclear energy and a desire to continue this interest.

This joint initiative at ANSTO has developed a new capability: solid surface radiolabelling to evaluate Auger emitting sources for next-generation targeted therapy.

ANSTO is working with government partners to ensure that radioactivity in drinking water supplied to Aboriginal communities is at levels considered safe for consumption.

International neutron scattering award for retired head of former Bragg Institute, Prof Robert Robinson

Innovative medical device Rhenium-SCT® therapy for non-melanoma skin cancer is now available in Australia

Thirty years of ANSTO's unique capability in monitoring fine particle pollution provides insight on bushfire smoke.

See details of previously published customer updates from our Health products team. 

Cyclotek and ANSTO have announced the launch of a Joint Venture (JV), to establish Australia’s first GMP (Good Manufacturing Practice) theranostics facility starting in Melbourne, Australia.

Doping with transition metals produced stability in bismuth oxide.